UPMC Health Plan achieves high ratings in provider satisfaction
Aug. 2023Important Notices
In 2022, 95 percent of physician practice survey respondents indicated they would recommend UPMC Health Plan to other physician practices. In addition, respondents ranked UPMC Health Plan in the 95th percentile when comparing UPMC Health Plan to other Health Plans with whom they participate.
UPMC Health Plan contracts with Press Ganey, formerly SPH, to measure provider satisfaction levels and to meet one or more NCQA Health Plan Accreditation Standards. Press Ganey incorporates a percentile ranking to allow health plans to compare performance to a cohort of similar health plans who initiate a provider satisfaction survey.
You may be a randomly selected provider invited to participate in the 2023 survey that will begin this month! The survey will ask for feedback on your experience with UPMC Health Plan. Watch for an invitation in the mail or via email later this month.
UPMC Health Plan contracts with Press Ganey, formerly SPH, to measure provider satisfaction levels and to meet one or more NCQA Health Plan Accreditation Standards. Press Ganey incorporates a percentile ranking to allow health plans to compare performance to a cohort of similar health plans who initiate a provider satisfaction survey.
You may be a randomly selected provider invited to participate in the 2023 survey that will begin this month! The survey will ask for feedback on your experience with UPMC Health Plan. Watch for an invitation in the mail or via email later this month.
Recent Announcements
Voluntary nationwide recall: Atorvastatin (Alkem – October)
Ascend Laboratories LLC is recalling multiple lots of Atorvastatin Calcium Tablets USP. Atorvastatin is used for the treatment of high cholesterol and to reduce the risk of certain cardiovascular events, such as heart attack and stroke.Nov. 2025Pharmacy Updates
October 2025 UPMC for You and UPMC Community HealthChoices formulary update
Effective Oct. 1, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to nonparticipation in the Medicaid Drug Rebate Program.Oct. 2025Pharmacy Updates
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates